

## Nectar Lifesciences Ltd.



Ref No.: NLL\CS\2015-89

May 14, 2015

To

1. National Stock Exchange of India Limited  
G' Block, Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), MUMBAI – 400 051.
2. BSE Limited  
Phiroze Jeejeebhoy Towers, Dalal Street,  
MUMBAI – 400 001.

**Ref: Information under Clause 36 of the Listing Agreement**

**Sub. Investors Press Release**

Dear Sirs,

Please find attached herewith an Investor Press release that "Nectar Lifesciences Ltd. bags ANVISA (Brazil) cGMP for Cephalosporin API's manufacturing facility."

This is for your information and necessary dissemination to investors.

Thanking you,

Yours faithfully,

For Nectar Lifesciences Limited

Director  
Chief Executive Officer & Director

Corporate Office : S.C.O. 38-39, Sector 9-D, Chandigarh-160 009 (India) Tel. : +91-172-3047777 Fax : +91-172-3047755  
E-mail : sales@necLife.com Website : www.necLife.com  
CIN : L24232 PB1995 PLC 016664

Regd. Office & Works : VIII, Saidgura, Teh. Dera Bassi, Distt. Mohali (Punjab) Near Chandigarh (INDIA)  
Tel. : +91-1762-308000, 308001 Fax : +91-1762-281187, 308135





## NECTAR LIFESCIENCES LIMITED

CIN: L24232PB1995PLC016664

Regd. Office: Village Saidpura, Tehsil – Derabassi, Distt. S.A.S Nagar (Mohali) Punjab – 140507, India.  
Ph: 01762-308000, 308001; Fax: 01762-308135, Email: [sunderlal@neclife.com](mailto:sunderlal@neclife.com), Website: [www.neclife.com](http://www.neclife.com)  
Corporate Office: Sco 38-39, Sector 9 D, Madhya Marg, Chandigarh 160009, U.T., India

For immediate release

### ***Nectar Lifesciences Ltd. bags ANVISA (Brazil) cGMP for Cephalosporin API's manufacturing facility***

**Chandigarh, 14 May, 2015**

Nectar Lifesciences Limited (NecLife), the fast-growing manufacturer of generic pharmaceutical active pharmaceutical ingredients (APIs) and formulation products has received ANVISA cGMP ("Current Good Manufacturing Practices") approval for Brazil for its Cephalosporin APIs' manufacturing facility in Dera Bassi, Punjab. The regulatory authority concluded that the facility, systems and practices comply with ANVISA cGMP requirements.

The facility is already approved by various international regulatory agencies such as US-FDA, MCC – South Africa, PMDA – Japan, OGYI-Hungary and KFDA- South Korea.

Brazil market for Cephalosporin's' is currently valued at USD 300 Mio. between injectable and oral molecules. NecLife has highest capacities globally of all the approved molecules in Cephalosporin. This approval opens up very valuable market for NecLife for API's as well as formulations for which Unit-6 located in Baddi is already approved by the ANVISA authority.

#### **About Nectar Lifesciences Limited (NecLife)**

Established in 1995, NecLife (BSE code: 532649, NSE Id: NecLife, ISIN Id: INE023H01027) is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). NecLife is one of the largest manufacturers of cephalosporin range of products and has an established brand presence in 20 states across India and 55 countries across five continents. NecLife has a global leadership position in 3 oral molecules and 2 sterile molecules. The Company has 11 manufacturing facilities – eight in Derabassi, Punjab (API and menthol units), two in Baddi, Himachal Pradesh (FDF and EHGC plants) and one in Jammu (menthol plant). NecLife's products include Oral and sterile cephalosporin APIs, FDFs, Empty hard gelatin capsules and Menthol and allied products.

Additional information on NecLife is available on the Company website [www.neclife.com](http://www.neclife.com).

#### **Investor contacts**

**Dinesh Dua**

Nectar Lifesciences Limited

Phone: +91 172 304 7766

Fax: +91 172 507 9049

Email: [dinesh.dua@neclife.com](mailto:dinesh.dua@neclife.com)

**Note:** This document contains 'forward-looking' statements at places. The Company has operations across several segments of business and remains subject to undetermined contingencies and risks. Nectar Lifesciences would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.